Biosimilars are a small part of the overall market for biologics, which accounted for $277 billion in sales globally in 2017 and is projected to reach $452 billion by 2022. The European Union leads...

Read more

Orphan drugs represent a niche sector in the global pharmaceutical market, but have accounted for approximately 40% of new drug approvals in the US over the past three years. Traditionally the focus...

Read more